CTOs on the Move

MD Revolution

www.mdrevolution.com

 
MD Revolution harnesses the power of digital health technology to predict, prevent, and reverse chronic disease – and lower healthcare costs. MD Revolution is a transformational digital health provider that delivers a proven population health management service. Our SaaS solution, RevUp, has revolutionized the approach to behavior change for lifestyle diseases including diabetes, obesity, and heart disease. Participants on RevUp receive actionable feedback based on personal health data gathered from wearables and apps. Predictive analytics drive real-time identification of individuals that will or will not achieve desired health outcomes, thereby allowing clinicians and health coaches to focus on participants who require more ...
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million
  • www.mdrevolution.com
  • 9191 Towne Centre Drive, Suite 510
    San Diego, CA USA 92122
  • Phone: 858.847.5064

Executives

Name Title Contact Details

Funding

MD Revolution raised $23M on 12/07/2015

Similar Companies

Comprehensive Health Services

Founded in 1975, CHS is the industry's trusted provider of onsite health centers and national examination programs.

Hims & Hers Health,

Hims is a company that provides telemedicine and e-commerce solutions for mens health and wellness.

HMR Veterans Services

HMR Veterans Services is a company that provides management and consulting services for State Veterans Homes, with a focus on improving the long term care needs of American Veterans.

Outcome Concept Systems

Outcome Concept Systems is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.